Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;25(33):1900538.
doi: 10.2807/1560-7917.ES.2020.25.33.1900538.

Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018

Affiliations

Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018

Sylvie Escolano et al. Euro Surveill. 2020 Aug.

Erratum in

Expression of concern in

  • Expression of concern for Euro Surveill. 2020;25(33).
    Eurosurveillance editorial team. Eurosurveillance editorial team. Euro Surveill. 2020 Aug;25(34):200827ec. doi: 10.2807/1560-7917.ES.2020.25.34.200827ec. Epub 2020 Aug 24. Euro Surveill. 2020. PMID: 32840204 Free PMC article. No abstract available.

Abstract

Background Rotavirus is a major cause of severe gastroenteritis in children worldwide. The disease burden has been substantially reduced in countries where rotavirus vaccines are used. Given the risk of vaccine-induced intussusception, the benefit–risk balance of rotavirus vaccination has been assessed in several countries, however mostly without considering indirect protection effects. Aim We performed a benefit–risk analysis of rotavirus vaccination accounting for indirect protection in France among the 2018 population of children under the age of 5 years. Methods To incorporate indirect protection effects in the benefit formula, we adopted a pseudo-vaccine approach involving mathematical approximation and used a simulation design to provide uncertainty intervals. We derived background incidence distributions from quasi-exhaustive health claim data. We examined different coverage levels and assumptions regarding the waning effects and intussusception case fatality rate. Results With the current vaccination coverage of < 10%, the indirect effectiveness was estimated at 6.4% (+/− 0.4). For each hospitalisation for intussusception, 277.0 (95% uncertainty interval: (165.0–462.1)) hospitalisations for rotavirus gastroenteritis were prevented. Should 90% of infants be vaccinated, indirect effectiveness would reach 57.9% (+/− 3.7) and the benefit–risk ratio would be 192.4 (95% uncertainty interval: 116.4–321.3). At a coverage level of 50%, indirect protection accounted for 27% of the prevented rotavirus gastroenteritis cases. The balance remained in favour of the vaccine even in a scenario with a high assumption for intussusception case fatality. Conclusions These findings contribute to a better assessment of the rotavirus vaccine benefit–risk balance.

Keywords: Rotavirus vaccine; benefit-risk ratio; indirect protection; intussusception; rotavirus gastroenteritis; simulation analysis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Illustration of rotavirus vaccine protection against gastroenteritis in children
Figure 2
Figure 2
Number of hospitalisations prevented by direct and indirect protection, obtained under several scenarios of rotavirus vaccine coverage, France, 2018 (n = 20,000 simulations)
Figure 3
Figure 3
Number of vaccine-prevented deaths from rotavirus gastroenteritis in children under 5 years of age (benefit) vs vaccine-related deaths from intussusception in infants under 1 year of age (risk), France, 2018 (n = 20,000 simulations)

Similar articles

References

    1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565-72. 10.3201/eid0905.020562 - DOI - PMC - PubMed
    1. Platts-Mills JA, Steele AD. Rotavirus vaccine impact in Africa: greater than the sum of its parts? Lancet Glob Health. 2018;6(9):e948-9. 10.1016/S2214-109X(18)30356-5 - DOI - PubMed
    1. Leshem E, Moritz RE, Curns AT, Zhou F, Tate JE, Lopman BA, et al. Rotavirus vaccines and health care utilization for diarrhea in the United States (2007-2011). Pediatrics. 2014;134(1):15-23. 10.1542/peds.2013-3849 - DOI - PMC - PubMed
    1. Poelaert D, Pereira P, Gardner R, Standaert B, Benninghoff B. A review of recommendations for rotavirus vaccination in Europe: Arguments for change. Vaccine. 2018;36(17):2243-53. 10.1016/j.vaccine.2018.02.080 - DOI - PubMed
    1. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J. 2011;30(1) Suppl;S1-5. 10.1097/INF.0b013e3181fefa1f - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources